Suven Life Sciences Limited has informed the Exchange about Copy of Newspaper Publication - Results
SUVEN · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Suven Life Sciences has published its audited financial results for the quarter and full year ended March 31, 2025, in Business Standard and Andhra Prabha, as required under SEBI listing rules. Standalone total income from operations for Q4 FY25 stood at Rs 146.70 lakhs, down from Rs 238.52 lakhs in Q4 FY24, while full-year standalone income was Rs 665.58 lakhs. The company reported a standalone net loss of Rs 4,707.98 lakhs for FY25, sharply wider than the Rs 412.63 lakhs loss in FY24. On a consolidated basis, the FY25 net loss ballooned to Rs 16,074.50 lakhs (before tax), compared to Rs 2,754.31 lakhs in the previous year. Loss per share for the year stood at Rs 2.16 (standalone) and Rs 7.37 (consolidated), indicating significant deterioration in profitability.
The widening losses year-on-year on both standalone and consolidated bases signal ongoing financial stress and are likely to be viewed negatively by shareholders, potentially weighing on the stock price in the near term.